KEGG   DRUG: Futermestotug
Entry
D13270                      Drug                                   
Name
Futermestotug (USAN/INN)
Formula
C6486H9990N1730O2014S44
Exact mass
145746.0193
Mol weight
145836.04
Sequence
(Heavy chain)
EVQLVESGGG LVQPGGSLRL SCAASGFTFS SYTMSWVRQA PGKGLEWVAT ISRGGGYTSY
PDSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARED YGSSYVHWFA YWGQGTLVTV
SAASTKGPSV FPLAPSSKST SGGTAALGCL VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ
SSGLYSLSSV VTVPSSSLGT QTYICNVNHK PSNTKVDKKV EPKSCDKTHT CPPCPAPELL
GGPSVFLFPP KPKDTLMISR TPEVTCVVVD VSHEDPEVKF NWYVDGVEVH NAKTKPREEQ
YNSTYRVVSV LTVLHQDWLN GKEYKCKVSN KALPAPIEKT ISKAKGQPRE PQVYTLPPSR
EEMTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTTP PVLDSDGSFF LYSKLTVDKS
RWQQGNVFSC SVMHEALHNH YTQKSLSLSP GK
(Light chain)
DIQMTQSPSF LSASVGDRVT ITCRAGENIY SYLAWYQQKP GKAPKLLIYN ARTLAEGVPS
RFSGSGSGTE FTLTISSLQP EDFATYYCQH HYGSPRTFGG GTKLEIKRTV AAPSVFIFPP
SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
(Disulfide bridge: H22-H96, H149-H205, H225-L214, H231-H'231, H234-H'234, H266-H326, H372-H430, H'22-H'96, H'149-H'205, H'225-L'214, H'266-H'326, H'372-H'430, L23-L88, L134-L194, L'23-L'88, L'134-L'194)
  Type
Peptide
Class
Antineoplastic
 DG02938  Immune checkpoint inhibitor
Efficacy
Antineoplastic, Immune checkpoint inhibitor, Anti-CTLA4 antibody
  Type
Monoclonal antibody
Comment
Treatment of solid tumors
Target
CTLA4 (CD152) [HSA:1493] [KO:K06538]
  Pathway
hsa04514  Cell adhesion molecule (CAM) interaction
hsa04660  T cell receptor signaling pathway
Brite
Drug groups [BR:br08330]
 Antineoplastic
  DG02938  Immune checkpoint inhibitor
   D13270  Futermestotug
Target-based classification of drugs [BR:br08310]
 Cell surface molecules and ligands
  Other cell surface molecules
   Immune checkpoints
    CTLA4 (CD152)
     D13270  Futermestotug (USAN/INN)
Other DBs
CAS: 3014361-57-7
PubChem: 527701173
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system